One-sentence summary of key findings: AVITA Medical (RCEL) is a small-cap therapeutic wound care company centered on its innovative RECELL autologous cell harvesting system for burns and skin defects, demonstrating accelerating revenue growth (e.g., Q2 2026 up 18% YoY), improving margins, and mostly positive analyst sentiment toward profitability milestones, while facing persistent losses, cash constraints, and reimbursement risks as a single-product focused entity.[[1]](https://finance.yahoo.com/quote/RCEL/)[[1]](https://finance.yahoo.com/quote/RCEL/)
Fact: AVITA Medical, Inc. (formerly AVITA Therapeutics, Inc., name changed December 2020) develops and commercializes point-of-care autologous skin restoration technologies. Its flagship RECELL System produces "Spray-On Skin" cells from a small patient skin sample in ~30 minutes for thermal burns, full-thickness skin defects, and stable vitiligo repigmentation. Additional products include RECELL GO variants, PermeaDerm (biosynthetic wound matrix), and Cohealyx (collagen-based dermal matrix). It operates primarily in the US with presence in Japan, EU, Australia, and UK; serves hospitals, burn/trauma centers, and distributors. Headquartered in Valencia, California; ~226 full-time employees; fiscal year ends December 31. Founded December 1992. Website: avitamedical.com. IR: ir.avitamedical.com.[[1]](https://finance.yahoo.com/quote/RCEL/)[[2]](https://seekingalpha.com/symbol/RCEL)
History (Fact): Technology roots trace to the 1990s; FDA PMA approval for RECELL in 2018 marked US commercialization start. Expanded indications (e.g., full-thickness defects) and product line (RECELL GO, Cohealyx) in recent years. Publicly traded on NASDAQ as RCEL. Focus shifted heavily to US market despite some international approvals.[[3]](https://www.marketwatch.com/investing/stock/rcel)
Interpretation: The company positions itself as a transformative acute wound care player with proprietary IP barriers, but remains largely a single-product story reliant on RECELL adoption.
Uncertainty & Limitations: Long-term success depends on regulatory expansions, reimbursement stability, and competition from evolving standards of care (e.g., traditional skin grafts); data drawn from company filings and secondary sources as of August 2026—subject to updates in future 10-Q/10-K reports.
Fact: As of early August 2026 data points:
Interpretation: Significant outperformance vs. broader market in recent periods suggests momentum from operational updates, though small-cap med-tech stocks like RCEL exhibit high volatility tied to clinical/commercial news.
Uncertainty: Past performance is not indicative of future results; returns exclude dividends (none paid).
Links for more information: Yahoo Finance RCEL | Company IR Stock Info | Macrotrends Historical Prices
Fact (TTM / Recent): Revenue (TTM) ~$72.35M; Net loss (TTM) ~$45.34M; Diluted EPS (TTM) -$1.56; Profit margin ~-63%; ROA (ttm) ~-41%; Cash (mrq) ~$14.26M. FY2025 revenue $71.6M (↑11% from $64.3M in FY2024). Q2 2026 revenue $21.7M (↑18% YoY, record gross margin 81.9%); net loss improved to ~$7.7M. Earlier quarters showed variability (e.g., reimbursement impacts in 2025). Company raised 2026 revenue guidance to $86–$89M; expects Q4 2026 cash flow breakeven.[[1]](https://finance.yahoo.com/quote/RCEL/)[[5]](https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-reports-fourth-quarter-and-full-year-2025)[[6]](https://www.stocktitan.net/news/RCEL/)
| Period | Revenue | YoY Change | Net Loss / EPS | Notes |
|---|---|---|---|---|
| FY 2024 | $64.3M | — | ~$61.8M loss (full year context) | Baseline |
| FY 2025 | $71.6M | +11% | Continued losses | Within revised guidance |
| Q2 2026 | $21.7M | +18% | ~$7.7M loss (~$0.25/share) | Record margin; raised FY guidance |
| TTM (as of ~Aug 2026) | ~$72.35M | — | ~$45.34M loss; EPS -$1.56 | — |
Interpretation: Revenue trajectory positive with margin expansion and new product contributions (RECELL ~$18.5M in Q2 example); path to breakeven/profitability highlighted in recent releases as key catalyst.
Uncertainty & Data Limitations: Financials are unaudited estimates or from press releases/TTM aggregates; actual results may differ (e.g., due to reimbursement timing, inventory, or clinical trial outcomes). Cumulative deficit ~$360M as of end-2024. Assumptions include continued commercial execution and no major adverse regulatory events. Flag: Small sample of quarters; forward guidance subject to revision.[[7]](https://www.sec.gov/Archives/edgar/data/1762303/000095017025020026/rcel-20241231.htm)
Links for more information: IR Homepage & Earnings Releases | Yahoo Financials | Latest 10-K (SEC)
Fact: Consensus generally "Moderate Buy" to "Strong Buy" across 6–8 analysts (as of Aug 2026 data). Average 12-month price target ~$8–$9 (range low ~$6, high ~$12+). Recent actions: BTIG upgraded to Buy (PT $7) on Aug 7, 2026; TD Cowen reiterated Buy (PT raised previously to $12); Lake Street Buy (upgrades/reaffirms); some neutral or Sell ratings (e.g., Weiss). ~50–67% Buy ratings in samples.[[1]](https://finance.yahoo.com/quote/RCEL/)[[8]](https://www.marketbeat.com/stocks/NASDAQ/RCEL/forecast/)[[8]](https://www.marketbeat.com/stocks/NASDAQ/RCEL/forecast/)
| Analyst / Firm | Recent Action | Rating | Price Target | Date (approx.) |
|---|---|---|---|---|
| BTIG | Upgrade | Buy | $7 | Aug 7, 2026 |
| TD Cowen | Reiterate / Raise | Buy | Up to $12 | Jun 2026 |
| Lake Street | Upgrade / Reaffirm | Buy | $6 (example) | May/Jun 2026 |
| Weiss Ratings | Reiterate | Sell (E+) | — | Jun 2026 |
Interpretation: Optimism centers on RECELL momentum, new indications/products (Cohealyx, RECELL GO), and guidance raises, supporting valuation upside from current levels.
Uncertainty: Analyst targets and ratings change frequently; consensus can shift with earnings misses or macro factors. Limited coverage depth for small-cap.
Links for more information: Yahoo Analyst Info | MarketBeat Forecasts | Seeking Alpha Analysis
Fact: Primary: ~140 US burn centers and ~300 burn surgeons (historically ~75% of severe burns); expanding to trauma centers (~10k additional eligible cases). Hospitals, treatment centers, and distributors. International sales growing (Japan noted). Revenue mix includes commercial RECELL, PermeaDerm, Cohealyx, and lease/international.[[7]](https://www.sec.gov/Archives/edgar/data/1762303/000095017025020026/rcel-20241231.htm)
Links: Company IR (earnings presentations detail customer metrics)
Fact: Company states no direct competition for RECELL due to unique autologous cell technology and IP/regulatory barriers. Broader wound care/advanced healing competitors include amniotic tissue products (e.g., MiMedx MDXG) and other med-device firms in burns/trauma (examples from peer lists: NPCE, KIDS, SI, CLPT, DCTH; also CERS, OFIX). Standard of care remains split-thickness skin grafts.[[9]](https://koalagains.com/stocks/NASDAQ/RCEL/competition)[[7]](https://www.sec.gov/Archives/edgar/data/1762303/000095017025020026/rcel-20241231.htm)
| Competitor / Peer | Focus Area | Comparison Note |
|---|---|---|
| MiMedx (MDXG) | Amniotic tissue wound products | Direct wound care overlap |
| NeuroPace (NPCE), OrthoPediatrics (KIDS), etc. | Specialized med devices | Peer group for small-cap devices |
| Various (e.g., traditional graft suppliers) | Skin grafts / standard care | Indirect; RECELL aims to reduce need |
Interpretation: Differentiation via speed, reduced donor site morbidity, and point-of-care use positions RECELL favorably, but execution and cost-effectiveness vs. alternatives are key.
Uncertainty & Limitations: Competitive landscape evolves with new technologies; no comprehensive independent verification of "no direct competition" claim beyond company statements. Data as of mid-2026 sources.
Links for more information: Competitive Analysis | MarketBeat Peers | 10-K Competition Section
Additional recent news highlights (for context): Q2 2026 earnings beat with guidance raise and breakeven outlook; government contract potential; clinical data on Cohealyx acceleration; conference participation. Full details on IR site or Yahoo News.
Overall Data Notes: All information synthesized from publicly available web sources (Yahoo Finance, company IR, SEC, analyst sites) as of August 7, 2026 crawl dates. Financial figures are approximate/TTM aggregates and should be verified against latest filings. This is not investment advice; small-cap biotech/med-device investments carry high risk of volatility and dilution. Assumptions include stable regulatory environment and no major litigation or macro disruptions.